About Keratin, type I cytoskeletal 15
Keratin, type I cytoskeletal 15 (KRT15) is a protein
from Homo sapiens identified by UniProt accession
P19012, 456 residues long.
MolForge cross-references it against 0 known binders and
191 disease associations.
Target properties
| Protein name | Keratin, type I cytoskeletal 15 |
| UniProt accession | P19012 |
| Gene | KRT15 |
| Organism | Homo sapiens |
| Length | 456 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (191)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.19
- prostate adenocarcinoma · score 0.19
- clear cell renal carcinoma · score 0.18
- glioblastoma multiforme · score 0.18
- esophageal cancer · score 0.14
- Alzheimer disease · score 0.14
- multiple sclerosis · score 0.14
- neurodegenerative disease · score 0.14
- lysosomal storage disease · score 0.14
- Parkinson disease · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P19012-F1 | alphafold | PREDICTED | 74.18 | — |
Amino-acid sequence (456 residues)
MTTTFLQTSS STFGGGSTRG GSLLAGGGGF GGGSLSGGGG SRSISASSAR FVSSGSGGGY GGGMRVCGFG GGAGSVFGGG FGGGVGGGFG GGFGGGDGGL LSGNEKITMQ NLNDRLASYL DKVRALEEAN ADLEVKIHDW YQKQTPTSPE CDYSQYFKTI EELRDKIMAT TIDNSRVILE IDNARLAADD FRLKYENELA LRQGVEADIN GLRRVLDELT LARTDLEMQI EGLNEELAYL KKNHEEEMKE FSSQLAGQVN VEMDAAPGVD LTRVLAEMRE QYEAMAEKNR RDVEAWFFSK TEELNKEVAS NTEMIQTSKT EITDLRRTMQ ELEIELQSQL SMKAGLENSL AETECRYATQ LQQIQGLIGG LEAQLSELRC EMEAQNQEYK MLLDIKTRLE QEIATYRSLL EGQDAKMAGI AIREASSGGG GSSSNFHINV EESVDGQVVS SHKREI
Explore Keratin, type I cytoskeletal 15 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets